MetaVia Inc. Price & Performance (MTVA)

MetaVia Inc. is preparing to release top-line data from its Phase 1 MAD Part 2 trial for DA-1726, targeting obesity treatment, in April 2025. This follows positive results from a Phase 2a trial of DA-1241 for MASH, showcasing metabolic advancements. The company's financial runway is projected to last until Q3 2025.123

MetaVia's stock is gaining attention with a "Strong Buy" rating and a 12-month target price of $12. Analysts highlight the company's potential in cardiometabolic therapies, including DA-1241 and DA-1726. Despite financial challenges, the company’s clinical progress is seen as a promising indicator for future growth.145

MetaVia reported a net loss of $27.6 million for 2024, driven by increased R&D spending on its cardiometabolic drug pipeline. With $16 million in cash reserves, the company expects to sustain operations into Q3 2025. Analysts remain optimistic about its clinical advancements and market potential.236